Hepatitis C Treatment Uptake Following Dried Blood Spot Testing for Hepatitis C RNA in New South Wales, Australia: The NSW DBS Pilot Study.
DBS
HCV
direct-acting antivirals
models of care
testing
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
03
07
2023
accepted:
18
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Dried blood spot (DBS) testing for hepatitis C virus (HCV) RNA provides a sampling option that avoids venepuncture and can be carried out in a nonclinical setting. Large-scale evaluations are needed to understand how DBS testing can reduce HCV burden. This study estimated prevalence of, and factors associated with, HCV RNA and treatment initiation among people enrolled in a state-wide pilot of people testing in the NSW DBS Pilot in New South Wales, Australia. People at risk of HIV/HCV could participate via (1) self-registration online with a DBS collection kit delivered and returned by conventional postal service; or (2) assisted DBS sample collection at a community site or prison. Logistic regression was used to identify factors associated with detectable HCV RNA and treatment initiation within 6 months of testing. Between September 2017 and December 2020, 5960 people were tested for HCV (76% men, 35% Aboriginal and/or Torres Strait Islander, 55% recently injected drugs): 21% online self-registration, 34% assisted registration in the community, 45% assisted registration in prison. Fifteen percent had detectable HCV RNA (878/5960). Overall, 44% (n = 386/878) of people with current HCV initiated treatment within 6 months (13% online self-registration, 27% assisted registration in the community, 61% assisted registration in prison). Testing in prison compared with the community (adjusted odds ratio [aOR], 4.28; 95% CI, 3.04-6.03) was associated with increased odds of treatment initiation. Being a woman compared with a man (aOR, 0.68; 95% CI, 0.47-0.97) was associated with reduced treatment initiation. The NSW DBS Pilot demonstrates the feasibility of using DBS to promote HCV testing and treatment in community and prison settings.
Sections du résumé
Background
UNASSIGNED
Dried blood spot (DBS) testing for hepatitis C virus (HCV) RNA provides a sampling option that avoids venepuncture and can be carried out in a nonclinical setting. Large-scale evaluations are needed to understand how DBS testing can reduce HCV burden. This study estimated prevalence of, and factors associated with, HCV RNA and treatment initiation among people enrolled in a state-wide pilot of people testing in the NSW DBS Pilot in New South Wales, Australia.
Methods
UNASSIGNED
People at risk of HIV/HCV could participate via (1) self-registration online with a DBS collection kit delivered and returned by conventional postal service; or (2) assisted DBS sample collection at a community site or prison. Logistic regression was used to identify factors associated with detectable HCV RNA and treatment initiation within 6 months of testing.
Results
UNASSIGNED
Between September 2017 and December 2020, 5960 people were tested for HCV (76% men, 35% Aboriginal and/or Torres Strait Islander, 55% recently injected drugs): 21% online self-registration, 34% assisted registration in the community, 45% assisted registration in prison. Fifteen percent had detectable HCV RNA (878/5960). Overall, 44% (n = 386/878) of people with current HCV initiated treatment within 6 months (13% online self-registration, 27% assisted registration in the community, 61% assisted registration in prison). Testing in prison compared with the community (adjusted odds ratio [aOR], 4.28; 95% CI, 3.04-6.03) was associated with increased odds of treatment initiation. Being a woman compared with a man (aOR, 0.68; 95% CI, 0.47-0.97) was associated with reduced treatment initiation.
Conclusions
UNASSIGNED
The NSW DBS Pilot demonstrates the feasibility of using DBS to promote HCV testing and treatment in community and prison settings.
Identifiants
pubmed: 38023551
doi: 10.1093/ofid/ofad517
pii: ofad517
pmc: PMC10665037
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad517Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. J.G. is a consultant/advisor for and has received research grants from AbbVie, Abbott, bioLytical, Camurus, Cepheid, Gilead Sciences, Hologic, Indivior, and Roche. P.R. has received research funding and honoraria for talks from Gilead Sciences. All other authors report no potential conflicts.
Références
J Viral Hepat. 2020 Mar;27(3):281-293
pubmed: 31698545
Am J Trop Med Hyg. 2018 Aug;99(2):256-265
pubmed: 29968557
Int J Drug Policy. 2015 Nov;26(11):1050-5
pubmed: 26118799
Int J Drug Policy. 2017 Sep;47:34-46
pubmed: 28797498
Int J Drug Policy. 2022 May;103:103654
pubmed: 35306279
Lancet Gastroenterol Hepatol. 2022 May;7(5):426-445
pubmed: 35303490
Lancet Glob Health. 2021 Apr;9(4):e431-e445
pubmed: 33639097
Drug Alcohol Rev. 2023 May 30;:
pubmed: 37254644
Frontline Gastroenterol. 2017 Jul;8(3):221-228
pubmed: 28839912
Viruses. 2023 Feb 13;15(2):
pubmed: 36851736
J Infect Dis. 2022 Sep 21;226(6):1005-1021
pubmed: 35150578
J Hepatol. 2023 Sep;79(3):635-644
pubmed: 37116714
J Infect Dis. 2021 Mar 3;223(5):818-826
pubmed: 32710758
Lancet Gastroenterol Hepatol. 2023 Mar;8(3):204-207
pubmed: 36773609
Lancet Gastroenterol Hepatol. 2023 Mar;8(3):253-270
pubmed: 36706775
Clin Infect Dis. 2013 Aug;57 Suppl 2:S51-5
pubmed: 23884066
Viruses. 2022 Jul 16;14(7):
pubmed: 35891535
Clin Infect Dis. 2021 Jul 1;73(1):e69-e78
pubmed: 32421194
J Viral Hepat. 2018 Nov;25(11):1236-1243
pubmed: 29757491
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):39-56
pubmed: 33217341
Viruses. 2022 Nov 07;14(11):
pubmed: 36366561
Int J Drug Policy. 2018 Nov;61:23-30
pubmed: 30388566
Int J Drug Policy. 2020 Jan;75:102608
pubmed: 31759307
Int J Drug Policy. 2023 Apr;114:103982
pubmed: 36863287
Int J Drug Policy. 2022 Jul;105:103706
pubmed: 35533635
J Clin Virol Plus. 2022 Aug;2(3):100093
pubmed: 35765384
Addiction. 2012 Jun;107(6):1090-6
pubmed: 22151433
JAMA Intern Med. 2022 May 1;182(5):494-502
pubmed: 35285851
Viruses. 2022 Jul 08;14(7):
pubmed: 35891474
J Clin Virol. 2019 Mar;112:40-44
pubmed: 30776575